000144701 001__ 144701
000144701 005__ 20240229112634.0
000144701 0247_ $$2doi$$a10.1007/s00399-019-00634-1
000144701 0247_ $$2pmid$$apmid:31463582
000144701 0247_ $$2ISSN$$a0938-7412
000144701 0247_ $$2ISSN$$a1435-1544
000144701 037__ $$aDKFZ-2019-02143
000144701 041__ $$ager
000144701 082__ $$a610
000144701 1001_ $$0P:(DE-HGF)0$$aLehmann, Lorenz H$$b0$$eFirst author
000144701 245__ $$a[Cardiac arrhythmias in oncological diseases, during radiotherapy, chemotherapy].
000144701 260__ $$aHeidelberg$$bSpringer$$c2019
000144701 3367_ $$2DRIVER$$aarticle
000144701 3367_ $$2DataCite$$aOutput Types/Journal article
000144701 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1568805694_5242$$xReview Article
000144701 3367_ $$2BibTeX$$aARTICLE
000144701 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144701 3367_ $$00$$2EndNote$$aJournal Article
000144701 520__ $$aPatients with oncological diseases frequently show cardiac arrhythmias. This is explained by an increased risk in this specific patient cohort and is frequently associated with specific oncological therapies. So far, it is unclear how to deal with the occurrence of arrhythmias diagnostically and therapeutically, since the current clinical data do not provide satisfying answers to these questions. Clinical care of high-risk patients in specialized teams with a focus on cardio-oncology is recommended. Based on the current clinical studies and the position papers of the European Society of Cardiology (ESC), we give a brief overview of arrhythmias in malignant diseases and their therapies.
000144701 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000144701 588__ $$aDataset connected to CrossRef, PubMed,
000144701 7001_ $$aKatus, Hugo A$$b1
000144701 7001_ $$aScholz, Eberhard P$$b2
000144701 773__ $$0PERI:(DE-600)1473154-x$$a10.1007/s00399-019-00634-1$$n3$$p268-273$$tHerzschrittmachertherapie & Elektrophysiologie$$v30$$x1435-1544$$y2019
000144701 909CO $$ooai:inrepo02.dkfz.de:144701$$pVDB
000144701 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000144701 9141_ $$y2019
000144701 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144701 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144701 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144701 9201_ $$0I:(DE-He78)G834-20160331$$kG834$$lAD Cardio Oncology$$x0
000144701 980__ $$ajournal
000144701 980__ $$aVDB
000144701 980__ $$aI:(DE-He78)G834-20160331
000144701 980__ $$aUNRESTRICTED